There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Centessa Pharmaceuticals (CNTA – Research Report), Lantheus (LNTH – Research Report) and Carisma Therapeutics (CARM – Research Report) with bullish sentiments.
Centessa Pharmaceuticals (CNTA)
In a report issued on November 29, David Risinger from Leerink Partners maintained a Buy rating on Centessa Pharmaceuticals. The company’s shares closed last Thursday at $6.00.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
Centessa Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $11.33, which is an 86.3% upside from current levels. In a report issued on November 15, Jefferies also upgraded the stock to Buy with a $11.00 price target.
See today’s best-performing stocks on TipRanks >>
Lantheus (LNTH)
In a report issued on November 29, Roanna Ruiz from Leerink Partners maintained a Buy rating on Lantheus, with a price target of $125.00. The company’s shares closed last Thursday at $71.62.
According to TipRanks.com, Ruiz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Lantheus has an analyst consensus of Strong Buy, with a price target consensus of $111.00, representing a 56.7% upside. In a report released yesterday, Brookline Capital Markets also initiated coverage with a Buy rating on the stock with a $100.00 price target.
Carisma Therapeutics (CARM)
Robert W. Baird analyst Jack Allen maintained a Buy rating on Carisma Therapeutics on November 28 and set a price target of $10.00. The company’s shares closed last Thursday at $2.40, close to its 52-week low of $2.18.
According to TipRanks.com, Allen is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Carisma Therapeutics is a Strong Buy with an average price target of $10.33, which is a 306.7% upside from current levels. In a report issued on November 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CNTA:
- Centessa’s (NASDAQ:CNTA) Narcolepsy Drug Wakes Up Investors
- Centessa upgraded to Buy from Hold at Jefferies
- Centessa reports Q3 EPS (40c), consensus (52c)
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
- CNTA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
